scholarly journals Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements

2020 ◽  
Vol Volume 12 ◽  
pp. 233-240 ◽  
Author(s):  
Helen Phillips-Jackson ◽  
Clive Hallam ◽  
Niamh Cullen ◽  
Terry Pearson ◽  
Mark Gilman ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Opioid Use Disorder ◽  
Budget Impact Analysis ◽  
Prolonged Release ◽  
Opioid Use ◽  
Resource Requirements ◽  
P Budget

scholarly journals A Budget Impact Analysis of the Collaborative Care Model for Treating Opioid Use Disorder in Primary Care

2019 ◽  
Vol 34 (9) ◽  
pp. 1693-1694 ◽  
Author(s):  
Chuan Mei Lee ◽  
Claudia Scheuter ◽  
Danielle Rochlin ◽  
Terry Platchek ◽  
Robert M. Kaplan
Keyword(s):  
Primary Care ◽  
Collaborative Care ◽  
Impact Analysis ◽  
Budget Impact ◽  
Opioid Use Disorder ◽  
Budget Impact Analysis ◽  
Opioid Use ◽  
Care Model ◽  
Collaborative Care Model

scholarly journals Budget impact analysis of the new reimbursement policy for day surgery in Thailand

2019 ◽  
Vol Volume 12 ◽  
pp. 41-55
Author(s):  
Rapeepong Suphanchaimat ◽  
Jutatip Thungthong ◽  
Kriddhiya Sriprasert ◽  
Kanjana Tisayaticom ◽  
Chulaporn Limwattananon ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Day Surgery ◽  
Budget Impact Analysis ◽  
Reimbursement Policy ◽  
P Budget

scholarly journals Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain

2019 ◽  
Vol Volume 11 ◽  
pp. 757-765
Author(s):  
Maria Cevey ◽  
Jaime Calvo-Alén ◽  
Carlos Crespo ◽  
Angel Robles-Marhuenda ◽  
Lee Smolen ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Systemic Lupus ◽  
P Budget

scholarly journals Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

2021 ◽  
Vol 8 ◽  
pp. 96-104
Author(s):  
Michele Basile ◽  
Lorenzo Somaini ◽  
Americo Cicchetti
Keyword(s):  
Impact Analysis ◽  
Drug Acquisition ◽  
Indirect Costs ◽  
Opioid Use Disorder ◽  
Point Of View ◽  
Cost Driver ◽  
Prolonged Release ◽  
Opioid Use ◽  
Clinic Attendance ◽  
Italian Context

Background: Opioid use disorder (OUD) is a disorder associated with significant rate of morbidity and mortality. Frequent clinic attendance for supervised consumption of sublingual buprenorphine is common. Prolonged-release buprenorphine (PRB) allows a management based on weekly or monthly subcutaneous injections, thus limiting the burdens of clinic attendance and the risks associated with sublingual formulations. Objective: To determine the price level of PRB that allows to obtain a neutral impact from the point of view of the economic resources absorbed, in comparison with the alternatives currently available in the Italian context for the management of patients suffering from OUD. Methods: The analysis assumes a daily PRB cost of €8.526 (neutral cost). The analysis aims to determine the economic impact associated with the introduction of PRB in the Italian context for the management of OUD patients. Results are expressed in terms of differential resourced absorbed in the alternative scenarios. A one-way sensitivity analysis was also carried out to test the robustness of the results. Results: The introduction of PRB implies an increase in the drug acquisition costs over the 5-year time horizon of €19.563.019,13: such costs are fully compensated by the other cost driver considered in the analysis (drug tests provided, health professionals’ time destined to the provision of the treatment, indirect costs, for savings equal to €6.167.026,94, €9.106.824,67 and €4.289.167,53 respectively) demonstrating its effectiveness in particular by an organizational point of view. Lower price levels for PRB would imply significant savings for the SSN. Conclusions: PRB resulted to be associated to a lower level of resources’ absorption in the Italian sector as compared with the available alternatives thus allowing to re-allocate health founds to other fields of the care sector ensuring greater safety for patients and a decreased misuse and diversion rate.

scholarly journals PIN150 Economic VALUE of Treatment and Vaccine Technologies to Address the COVID-19 Pandemic: A Cost-Effectiveness and Budget IMPACT Analysis

2020 ◽  
Vol 23 ◽  
pp. S568
Author(s):  
W. Padula ◽  
S. Malaviya ◽  
N. Reid ◽  
F. Chingcuanco ◽  
J. Ballreich ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Impact Analysis ◽  
Budget Impact ◽  
Economic Value ◽  
Budget Impact Analysis

scholarly journals AB0634 BUDGET IMPACT ANALYSIS OF BIOLOGICAL THERAPY COMPARED TO CONVENTIONAL SPONDYLOARTHRITIS TREATMENT, IN A FOURTH LEVEL HOSPITAL IN BOGOTA COLOMBIA

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1612.2-1613
Author(s):  
J. M. Bello-Gualtero ◽  
O. J. Calixto ◽  
G. Salguedo ◽  
Y. M. Chamorro-Melo ◽  
C. A. Camargo Rodríguez ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Annual Cost ◽  
Impact Analysis ◽  
Budget Impact ◽  
Biological Therapy ◽  
Biologic Therapy ◽  
Disease Diagnosis ◽  
Budget Impact Analysis ◽  
Military Hospital ◽  
Number Of Patients

Background:Spondyloarthritis refers to a family of diseases, of which ankylosing spondylitis and non-radiographic axial spondyloarthritis are responsible for axial impairment. Previously, the only treatment available were NSAIDs, which control activity and stop radiological progression, but at the expense of increased adverse effects, such as cardiovascular risk, dyspepsia and chronic renal failure. For the past 2 decades, biological therapy has been available, which means an increase in care costs.Objectives:The objective of this study is to perform a budget impact analysis of biologic therapy.Methods:To do a budget impact analysis from the perspective of the payer, comparing biological therapy with coventional therapy for the treatment of spondyloarthritis. Demographic characterization of the population attended at the Central Military Hospital. Time horizon from 2012 to 2018, taking the activity count according to the hospital’s billing and the prices of the activities of the state body SISMED. Exchange rates at the end of 2018.Results:The patients attended were 117, mostly men (63, 25%), average age 46, 4 years (SD 13), with disease diagnosis time of 9, 8 years (SD 9, 6). In the budget impact analysis, it is observed that 25% of patients were on DMARDs therapy, 22% with NSAIDs and 96% with biologic therapy. The average year/patient cost with NSAIDs alone would be EUR 381, with DMARDs only EUR 9,318 and, if only biological therapy was used, EUR 423. Within the total number of patients, the average annual cost, including the possibility of combining these drugs, amounted to EUR 5,403Conclusion:Including biological therapy in the care of patients with spondyloarthritis can increase up to 24 times the annual cost per patient. This increase is not only due to higher market value, it also relates to the need for more medical procedures and diagnostic follow-up tests.References:[1]Strömbeck, et al. Cost of Illness from the Public Payers’ Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care. J Rheumatol 2010;37;2348-2355.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document